linagliptin/metformin (Jentadueto®)

Reference No. 2446

Publication date:

14/08/2014

Last review date:

23/04/2019

Appraisal information

linagliptin/metformin (Jentadueto®) 2.5 mg/1000 mg film-coated tablet
linagliptin/metformin (Jentadueto®) 2.5 mg/850 mg film-coated tablet

Company:	Boehringer Ingelheim Ltd
BNF category:	Endocrine system
NMG meeting date:	18/06/2014
AWMSG meeting date:	16/07/2014

Submission Type:	Limited Submission
Status:	Recommended
Advice No:	2114
Ratification by Welsh Government:	13/08/2014

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of linagliptin and metformin as separate tablets.

Final Appraisal Recommendation (FAR)

Download

linagliptin-metformin (Jentadueto) 2446 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

linagliptin-metformin (Jentadueto) 2446 ASAR

Clinical Expert (CE) Summary

Download

linagliptin-metformin (Jentadueto) 2446 CE Summary